- President, Chief Executive Officer, and founder of Kite Pharma
- Arie Belldegrun, M.D., FACS, is President, Chief Executive Officer, and founder of Kite Pharma, and also serves as Chairman of the Company. He has had a distinguished tenure in the life sciences, having been closely involved with the founding and advancement of several successful biopharmaceutical companies. Prior to founding Kite, Dr. Belldegrun was the founding Vice-Chairman of the board of directors and Chairman of the Scientific Advisory Board of Cougar Biotechnology, acquired by Johnson & Johnson in 2009. Previously, Dr. Belldegrun founded and served as Chairman of the board of directors of Agensys, acquired by Astellas Pharma Inc. He currently serves as Chairman of Arno Therapeutics, Two River Group, and UroGen Pharma, Ltd. (formerly TheraCoat, Ltd.), and as a board member of Teva Pharmaceutical Industries Ltd. and Cell Design Labs. He is also a member of the Parker Institute for Cancer Immunotherapy’s Strategic Advisory Group. In addition, Dr. Belldegrun is Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. Prior to joining UCLA, he was at the National Cancer Institute/NIH as a research fellow in surgical oncology and immunotherapy under Dr. Steven A. Rosenberg. Dr. Belldegrun completed his M.D. at the Hebrew University Hadassah Medical School in Jerusalem, his post-graduate studies in Immunology at the Weizmann Institute of Science, and his residency in Urologic Surgery at Harvard Medical School. He has authored several books in oncology and more than 500 scientific and medical papers related to urological cancers, immunotherapy, gene therapy, and cancer vaccines. He is certified by the American Board of Urology, and is a Fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons.